Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study

Abstract

Background: The use of proton-pump inhibitors (PPIs) has increased over the last decade. The objective of this study was to provide detailed utilization data on PPI use over time, with special emphasis on duration of PPI use and concomitant use of ulcerogenic drugs. Methods: Using the nationwide Danish Prescription Registry, we identified all Danish adults filling a PPI between 2002 and 2014. Using descriptive statistics, we reported (i) the distribution of use between single PPI entities, (ii) the development in incidence and prevalence of use over time, (iii) measures of duration and intensity of treatment, and (iv) the prevalence of use of ulcerogenic drugs among users of PPIs. Results: We identified 1,617,614 adults using PPIs during the study period. The prevalence of PPI use increased fourfold during the study period to 7.4% of all Danish adults in 2014. PPI use showed strong age dependency, reaching more than 20% among those aged at least 80 years. The proportion of users maintaining treatment over time increased with increasing age, with less than10% of those aged 18-39 years using PPIs 2 years after their first prescription, compared with about 40% among those aged at least 80 years. The overall use of ulcerogenic drugs among PPI users increased moderately, from 35% of users of PPI in 2002 to 45% in 2014. Conclusions:The use of PPIs is extensive and increasing rapidly, especially among the elderly.

Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)

“…For this reason, when prescribing this class of drugs, an accurate evaluation of the risks/benefits ratio of long‐term use of PPI is formally recommended by the American Gastroenterological Association . In a nationwide Danish study, the prevalence of PPI use in adults increased from 2% in 2002 to 7.4% in 2014 and prolonged treatment was very common . Remarkably, PPI use increased with age; its prevalence among patients over 60 years old reaching 14.0% in men and 16.3% in women and exceeding 20% among patients aged ≥80 years .…”

Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression

“…Soon after the introduction of omeprazole, the first PPI, into the market, Jean Paul Galmiche, a leading French gastroenterologist, wrote a thoughtful article [8] anticipating that the unprecedented clinical efficacy of these drugs would have lead (patients and physicians alike) to addiction, and indeed, this is the case. Once on a PPI, the majority of patients stay on long-term PPIs, often indefinitely [9], especially the elderly [10]. …”

β-Lactams and β-Lactamase Inhibitors: An Overview

“…Another naturally occurring penicillin, penicillin V ( phenoxymethylpenicillin), in an oral formulation is still used therapeutically and prophylactically for mild to moderate infections caused by susceptible Streptococcus spp., including use in pediatric patients (Pottegard et al 2015). However, the selection of penicillin-resistant penicillinase-producing staphylococci in patients treated with penicillin G led to decreased use of this agent, and prompted the search for more penicillins with greater stability to the staphylococcal b-lactamases (Kirby 1944(Kirby , 1945Medeiros 1984).…”